BioSpace News Archive

Castor, an industry leader in modular, patient-centric, clinical trial technology, today announced the executive appointment of Tobias Schaefer as Chief Financial Officer (CFO).

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it has received notification from the Nasdaq Stock Market informing the Company that as of June 20, 2023 it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1).

Biotricity Inc. announced that it will host its Fiscal Year 2023 Financial Results and Business Update Call on Friday, June 30, 2023.

Panbela Therapeutics, Inc announces a poster presentation highlighting the results for CPP-1X (also known as α-Difluoromethylornithine (DFMO) or Eflornithine) in recent onset type 1 diabetes at the Endocrine Society meeting, which was held June 15-18, 2023.

Reneo Pharmaceuticals, Inc. today announced that it has been added to the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, according to a preliminary list of additions posted May 19.

Twist Bioscience Publishes Preclinical Data in Diabetes Validating GLP-1R Antagonist Antibody as Potential Treatment for Congenital Hyperinsulinism.

Acer Therapeutics Inc. today announced it has received $1,000,000 in funding in exchange for the issuance of an unsecured, subordinated promissory note for that principal amount to Christopher Schelling, the Company’s Chief Executive Officer and Founder, a member of the Company’s Board of Directors, and the beneficial owner of more than 10% of the Company’s outstanding common stock.

Artelo Biosciences, Inc. announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo, presented important new data from multiple preclinical studies regarding ART12.11, Artelo’s patented cannabidiol (CBD) cocrystal, on Sunday, June 25th, at the 33rd International Cannabinoid Research Society (ICRS) Symposium in Toronto, Ontario, Canada.

ORIC Pharmaceuticals, Inc. today has agreed to sell approximately 12.1 million shares of its common stock (or pre-funded warrants in lieu thereof) to a select group of institutional and accredited healthcare specialist investors in a private placement,

ABVC BioPharma, Inc. today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) as the new Chief Executive Officer (CEO).